Capricor
Los Angeles, US · 1 known investors
Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Founders & leadership
LS
Linda S. MarbanFounder
Board
LG
Louis GrasmickBoard director
LV
Louis V. ManzoBoard director
EM
Earl M. Collier, Jr.Board director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.5M disclosed across 1 round · 2012
▶$4.5MraisedJan 2012 · 3 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJan 2012 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Linda S. MarbanExecutive Officer, Director
- Louis GrasmickDirector
- Louis V. ManzoDirector
- Earl M. Collier, Jr.Director
- Offering amount
- $15M
- Amount sold
- $4.5M
- Minimum investment
- $250K
- Proceeds to insiders
- $200K
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $794.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $124.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Capricor do?
- Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
- Who founded Capricor?
- Capricor was founded by Linda S. Marban.
- Who are Capricor's investors?
- Capricor's investors include Broadview Ventures.
- How much funding has Capricor raised?
- Capricor has disclosed $4.5M raised across 1 round.
- Where is Capricor headquartered?
- Capricor is headquartered in Los Angeles, US.